Evidence · idea-003

In vitro diagnostic products properly labeled "For Research Use Only. Not for use in diagnostic procedures." under 21 CFR (Title 21 of the Code of Federal Regulations) 809.10(c) are not subject to FDA (US Food and Drug Administration) premarket notification or approval

FDA guidance "Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only" (issued November 2013) sets out when RUO labeling is defeated by the manufacturer's marketing conduct

Enforcement risk claim — marketing this material specifically to CLIA (Clinical Laboratory Improvement Amendments) laboratories for validating clinical tests is exactly the conduct the 2013 RUO guidance treats as evidence that a product is not truly research use only

CPT (Current Procedural Terminology) code 0340U exists and describes Natera's Signatera pan-cancer tumor-informed MRD assay from plasma

TAM (total addressable market) component 1 — the Medicare Clinical Laboratory Fee Schedule rate for 0340U was $3,500.00 for the 7/1/21-3/31/22 period

TAM component 3 — reference material and external QC spend runs roughly 0.5%-1.5% of laboratory test revenue for high-complexity molecular assays

TAM component 4 — addressable share assumption: the initial obtainable segment is the 30-60 US laboratories running or developing tumor-informed MRD assays, not the whole oncology molecular testing market

MolDX Billing and Coding article A58456, "MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers," exists in the CMS Medicare Coverage Database

Reimbursement — this product has no CPT/HCPCS code and none is achievable; it is a consumable sold to laboratories, and revenue depends entirely on the customer's reimbursed test volume

FDA's 2024 laboratory developed test final rule was vacated by a federal district court in March 2025, so LDT (laboratory-developed test)-based MRD assays remain under CLIA/CAP oversight rather than FDA premarket review

Technical/mechanism risk — producing commutable material with a stated uncertainty budget at 0.001%-0.01% VAF (variant allele frequency) is Poisson-limited at typical 10-30 ng cfDNA inputs, meaning the lowest panel levels may be irreducibly imprecise rather than merely hard to make

Competitive intensity — LGC Clinical Diagnostics (Seraseq), Revvity/Horizon Discovery, and Twist Bioscience all sell cfDNA/ctDNA reference materials today, but the Generator did not find a product specifically characterized in the sub-0.01% VAF MRD range on native-fragmentomic patient matrix

FTO (freedom to operate) — no blocking patent identified over contrived cfDNA reference material composition; risk sits mainly in fragmentomic-profile and variant-spiking methods held by sequencing incumbents. No specific patent number identified

Moat lever — the durable asset is the orthogonal characterization dataset and traceability/uncertainty documentation that a laboratory can paste into a CAP validation packet, plus lot-to-lot continuity once a lab has anchored its LoD claim to a given lot; the material itself is reproducible by any competent competitor

Capital intensity — first revenue is achievable on a low-single-digit-million budget: a small wet lab, a digital PCR platform, donor plasma sourcing, and ISO 17034-oriented documentation; no instrument development, no clinical trial, no premarket submission

Assumption (not a checkable fact) — the idea depends on MRD laboratories preferring a third-party commutable panel over the in-house contrived controls they already build, and on their being willing to anchor a published LoD claim to an external lot. There is no connector for laboratory purchasing preference and no primary research behind this; stated here so it stays visible

Laboratories running or developing tumor-informed MRD assays currently build in-house contrived controls and find them inadequate at sub-0.01% variant allele fraction

A CAP inspector or CLIA assessor accepts a third-party commutable reference panel with a published uncertainty budget as validation evidence supporting a laboratory's limit-of-detection claim

Laboratories will accept lot-to-lot continuity risk from a single external supplier for a limit-of-detection claim they publish

Assay-development scientists select reference material directly and can purchase it as a consumable, without a capital-procurement process

Reference-material purchasing at MRD laboratories is recurring, at a cadence tied to assay runs and periodic revalidation, rather than a one-time development purchase

The 30-60 laboratory segment can be reached by a direct technical sales motion without a distributor

Panel price multiplied by that laboratory count supports a standalone business rather than a product line inside a larger reagent company

Pooled human donor plasma can be sourced at a scale and consistency that preserves the native cell-free DNA fragmentomic profile lot over lot

Commutability against clinical patient samples can be demonstrated across the major tumor-informed MRD assay chemistries, rather than asserted from the matrix choice

Panel levels at the lowest allele fractions are stable through freeze-thaw, shipping and the stated shelf life within the published uncertainty budget

ISO 17034 reference-material-producer accreditation is achievable on the stated budget and timeline

Haystack MRD's analytical validation demonstrated a 95% limit of detection of 0.063 mean ctDNA molecules/mL and an analytical measurement range of 0.25-1,000 mean ctDNA molecules/mL

The CancerDetect (AlphaLiquid Detect) hybrid tumor-informed/tumor-agnostic MRD assay's analytical validation reached a limit of detection of 0.001% (10^-5) variant allele fraction at 99.9% specificity

The NeXT Personal ctDNA assay's analytical validation reported a 95% limit of detection (LOD95) of 3.45 parts per million (approximately 0.000345% VAF), linear from 0.8 to 300,000 ppm

The Invitae Personalized Cancer Monitoring assay's limit of detection ranged from 0.008% VAF at 60 ng cfDNA input to 0.05% VAF at 10 ng cfDNA input, both at greater than 99.9% sensitivity

A tumor-informed ctDNA monitoring method (GeneBits/umiVar) benchmarked on three commercial cfDNA reference standards (Twist Pan-Cancer v2, Horizon Multiplex I, Horizon OncoSpan) achieved a limit of detection as low as 0.0017% variant allele fraction with no false-positive calls in mutation-free reference samples

In a multi-manufacturer study of a multiplex cfDNA reference material, coefficient of variation increased with decreasing mutant allele fraction and poor repetition occurred when the allele fraction was lower than 0.5%, across eight manufacturers' NGS (next-generation sequencing) platforms

An 89-laboratory external quality assurance program for cfDNA variant testing used reference material with predicted allele fractions of 0.5%-2.5% and found greater than 92% of laboratories concordant by z-score proficiency testing

In the DYNAMIC-III randomized trial (n=968 evaluable stage III colon cancer patients), ctDNA-negative patients had a significantly higher 3-year recurrence-free survival than ctDNA-positive patients (87% versus 49%, P<0.001)

In the ALTAIR randomized phase 3 trial (n=243), post-adjuvant treatment triggered by ctDNA-detected molecular residual disease did not significantly improve disease-free survival versus placebo (hazard ratio 0.79, 95% CI 0.60-1.05, P=0.107), and the primary endpoint was not met

Natera reported that clinical molecular residual disease (Signatera) oncology test unit volume grew by 34,000 units in Q2 2026 versus Q1 2026, the largest sequential increase in the company's history to that date

Guardant Health reported that Guardant Reveal test volume grew more than 100% year-over-year in Q2 2026, its third consecutive quarter of greater than 100% year-over-year growth

LGC/SeraCare's Seraseq ctDNA Reference Material v4 product line's lowest characterized variant allele fraction is 0.1%, supplied in a vendor-described 'plasma like matrix' rather than pooled human donor plasma

Horizon Discovery (Revvity) cfDNA reference standards are manufactured from fragmented human cell-line genomic DNA (average 160 bp) spiked into a synthetic plasma matrix, with allele fractions offered down to 0.1%

By year 3, a third-party commercial reference panel captures at least a low double-digit percentage share of addressable US MRD-laboratory reference-material spend, rather than losing that spend to in-house contrived controls or the three incumbent commercial vendors

A molecular laboratory or assay manufacturer will pay a per-panel price materially above the incumbent commercial reference-material vendors' list price (LGC Seraseq, Horizon/Revvity HDx, Twist Bioscience) for a panel characterized into the sub-0.01% VAF range

The gross margin earned on the panel, once donor-plasma sourcing, orthogonal dPCR characterization, and ISO 17034-oriented documentation costs are included, is high enough to support a standalone reference-material business at the addressable laboratory count and purchase cadence

First commercial shipment of a characterized panel to a paying laboratory customer is achievable within the same low-single-digit-million capital budget and a calendar of roughly 9-15 months from a standing start

An existing reference-material vendor (LGC Clinical Diagnostics, Revvity/Horizon Discovery, or Twist Bioscience) would license or acquire sub-0.01%-VAF characterization and orthogonal dPCR quantification methodology rather than build it in-house, at a cost and calendar lower than fielding an independent direct-sales channel to the 30-60 laboratory segment

A quality control material whose entire purpose is validating a tumor-informed ctDNA minimal residual disease assay is not itself 'intended for use in the diagnosis, monitoring, or screening of neoplastic diseases' within the meaning of 21 CFR 862.9(c)(1) and 866.9(c)(1), such that the 510(k) exemptions at 862.1660 and 866.5910 are not withdrawn for either clinical-QC repositioning route

21 CFR 866.5910's generic type, quality control material for cystic fibrosis nucleic acid assays, is not read under 866.9(a) as a different intended use from a contrived cfDNA oncology minimal residual disease reference panel, such that a 510(k) is not required on that distinct ground

No live, enforceable US patent held by an incumbent cfDNA/ctDNA reference-material or liquid-biopsy manufacturer (including LGC Clinical Diagnostics/SeraCare, Revvity/Horizon Discovery, Twist Bioscience, Natera, Guardant Health, Illumina/Grail, Roche, or Bio-Rad) claims a method for preserving native cell-free DNA fragmentomic profile in a contrived plasma matrix, or for spiking characterized variant-bearing fragments at ultra-low (0.001%-0.5%) allele fraction with orthogonal dPCR quantification, in a way that reads on this candidate's mechanism

No CPT/HCPCS code, National Coverage Determination, Local Coverage Determination, or Medicare/Medicaid coverage determination applies to a commutable patient-matrix reference material panel of this kind, because it is purchased by a laboratory as an operating consumable rather than billed by the laboratory to a third-party payer as a separately reimbursable item

The specific sub-0.01%-VAF commutable-material composition and orthogonal dPCR characterization protocol described in this candidate's mechanism occupies available (unclaimed) patent scope

The reference-material and external-QC spend pool for tumor-informed ctDNA MRD assay validation is correctly sized as a share of downstream Medicare CLFS test revenue for CPT 0340U (rate x volume x QC-spend-share), rather than by a bottom-up per-laboratory annual reference-material spend estimate across the 30-60 addressable laboratories

The panel's characterization and value-assignment process at 0.001%-0.01% VAF can be performed repeatably across production lots without the value-assignment-error, stability-drift, or vial-to-vial-imprecision failure modes that account for a large share of FDA recalls recorded under product codes JJX and JJY (quality control/calibrator materials), the nearest analog device family.

A dPCR replicate series of at least 20 replicates per level, run at the panel's own stated 10-30 ng cfDNA input mass, for the panel's lowest target VAF levels (0.001%-0.01%), demonstrates a coefficient of variation and detected-vs-expected concordance consistent with a defensible, pre-specified uncertainty budget at those levels rather than being dominated by Poisson counting-statistics noise at the resulting expected mutant-molecule count

A single pooled-donor-plasma reference-material lot can simultaneously retain native background cfDNA composition sufficient to be considered commutable and carry an orthogonally dPCR-quantified ultra-low variant allele fraction spike (0.001%-0.01%) whose uncertainty budget is not degraded by that native background (endogenous low-frequency donor variants, fragment-size heterogeneity, or platform error rate approaching the same order of magnitude as the spiked signal)

FDA's guidance "Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only" (issued 2013-11-25, Docket No. 2011-D-0305), Section IV.B, names solicitation of business from clinical laboratories that do not perform research or clinical studies (e.g. a manufacturer's sales force making routine calls on them), provision of specialized technical support such as assistance performing clinical validation to clinical laboratories, and statements suggesting clinical laboratories can validate the test and then offer it as a laboratory-developed test, as examples of evidence that, under a totality-of-the-circumstances test, conflict with RUO or IUO labeling

The same guidance states, in Section II (p.6), that mere placement of an RUO or IUO label on an IVD product does not render it exempt from otherwise applicable clearance, approval, or other requirements, and that FDA may determine a device is intended for clinical diagnostic use based on other evidence, including how the device is marketed

CMS Medicare Coverage Database article A58456, "Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers," existed as the billing-and-coding companion to LCD L38816 (a Medicare local coverage determination number), provided conditional (not unconditional) coverage subject to criteria in the related LCD including a frequency limit of once per patient per cancer diagnosis absent a priori genetic-content change, and both the article and LCD carry a Retired status with revision-ending date 2026-02-05, consolidated into unified JE/JF jurisdiction documentation

Partial, non-substitute finding bearing on TAM component 1 (claim 9unconfirmed), in answer to REQ-0036 Populate data/hcpcs_payment_rates.csv and… — the same freshly fetched CMS Medicare Physician & Other Practitioners by Geography and Service national row for 0340U (Place_Of_Srvc=O, release fetched 2026-09-15, CY2024 claims) carries Avg_Sbmtd_Chrg=$4,944.1622, Avg_Mdcr_Alowd_Amt=$3,518.6835291, and Avg_Mdcr_Pymt_Amt=$3,518.6835291

CAP All Common Checklist item COM.40400 (release dated 2017-08-21) requires laboratories running laboratory-developed or modified FDA-cleared tests to establish analytical sensitivity (lower detection limit) and names no required material for doing so

CAP All Common Checklist item COM.40300 (release dated 2017-08-21) states that matrix-appropriate reference materials, patient specimens, or other commutable materials of known concentration 'may be used' to verify or establish accuracy - reference material is one permitted option, not a requirement

The 2017 AMP/CAP guideline for validating NGS oncology panels states laboratories 'should use' reference materials composed of well-characterized normal cell lines and cell-line mixtures to estimate performance specifications, and does not use the terms 'traceable', 'certified reference material' or 'ISO 17034'

ISO 17034:2016 specifies general requirements for the competence and consistent operation of reference material producers (not of laboratories using reference material) and supersedes ISO Guide 34:2009

A2LA states that new applicants complete accreditation within 5 months on average and a well-prepared applicant within three to six months - figures stated for all A2LA programs, not specifically ISO 17034

A2LA R101 (publication date 2026-09-01) grants accreditation for two years with a one-day surveillance assessment after the first year and a full reassessment every two years, and requires initial applicants to resolve all nonconformances within four months of the exit briefing

Neither A2LA nor PJLA publishes a fee schedule for ISO 17034 reference-material-producer accreditation; both direct applicants to a quote or estimate request

ATCC holds an ANAB ISO 17034 scope (certificate AR-1384, version 011 issued 2025-03-10, valid to 2027-03-17) covering nucleic-acid reference materials and certified reference materials characterized by methods including digital PCR for quantitative testing; the scope does not name human cell-free or tumour-derived DNA

The SeraCare Seraseq ctDNA Complete Reference Material AF0.5% product page states manufacture in cGMP-compliant, ISO 9001 and ISO 13485 certified facilities and makes no ISO 17034 accreditation statement

In a three-laboratory study of six commercial cfDNA reference materials against 42 patient plasma samples on a duplex-sequencing NGS assay, no reference material resembled native cfDNA in all performance metrics investigated

In the same six-material study, only the Twist cfDNA Pan-cancer reference material had an insert-size distribution similar to native cfDNA, while Horizon OncoSpan, Seraseq Myeloid, SensID and sheared Coriell NA24385 showed broad distributions comparable to mechanical DNA fragmentation

In the same six-material study, the Twist and SeraCare reference materials showed significantly more low-VAF variants than the patient samples in all five VAF intervals from 0.01% to 5%, attributed by the authors to variants introduced by the manufacturing process

In an independent study of eight Seraseq NIPT reference-material genotypes in six replicates each, fragment-size profiles showed slight but consistent deviations from natural maternal plasma, notably after size selection, which the authors concluded did not affect analytical performance

A 2014 LGC cfDNA standardisation paper converts DNA mass to copy number at 3.3 pg per human haploid genome (about 300 genome equivalents per ng)

In the FNIH Biomarkers Consortium ctDNA quality-control-material study (four laboratories, materials from three manufacturers at 5%-0% VAF), every assay showed dropouts at 0.1% VAF, with the NIST ddPCR site using 9 ng (about 2,700 genomic copies) of input

KRISS nucleosomal-DNA EGFR reference materials (2026) were value-assigned by ddPCR at a lowest level of 0.25%-0.32% VAF with expanded uncertainties of 33%-90% relative, and the nominal level below that was reported as not detected

In the same KRISS study (over 10,000 accepted droplets per QX200 reaction), the limit of blank derived from more than 85 wild-type reactions was 0.04%-0.11% VAF and the limit of detection was below 0.15%

The Seraseq ctDNA MRD Panel Mix datasheet reports dPCR only for the 0.5% tumor-content (0.25% VAF) blend and reports 4 NGS-observed variant copies across 4 of 100 variants at the 0.005% blend, with no uncertainty stated at any level

claim 1unconfirmed of US9499870B2 claims a cell-free nucleic acid diagnostic proficiency-testing standard composition comprising nucleosomal nucleic acid preparations derived from two different cell sources

claim 1unconfirmed of US11215622B2 claims generating cfDNA reference material by formaldehyde fixation, acoustic shearing to 1-5 kbp and enzymatic linker digestion to nucleosome material of 147 to 195 bp

KRISS nucleosomal-DNA EGFR reference materials (0-5% nominal VAF), made with an MNase-based kit, had a fragment-size distribution of about 150-170 bp, were supplied in Tris-EDTA buffer rather than plasma, and were stable for three years at -70 C

SeraCare lists the Seraseq ctDNA MRD Panel Mix as four 200 ng vials of purified DNA in Tris/EDTA buffer at tumor-fraction levels of 0%, 0.5%, 0.05% and 0.005%

Natera's Form 10-Q for the quarter ended 2026-06-30 states total oncology units processed were approximately 296,700

Natera's Form 10-Q for the quarter ended 2026-03-31 states oncology units processed were approximately 258,900

Natera's Q2 2026 earnings presentation (Form 8-K Exhibit 99.2) states approximately 283K clinical MRD oncology tests in Q2 2026 versus 181K in Q2 2025

No Natera Form 10-Q or 10-K filed 2023-2026 contains the phrase 'clinical MRD'; the phrase appears only in Form 8-K Exhibit 99 earnings materials

Guardant Health's Form 10-Q for the quarter ended 2026-06-30 reports a volume of approximately 104,000 for that quarter versus approximately 64,000 a year earlier, which its same-day earnings release describes as oncology tests, with no Reveal-specific count

On 2026-09-25 Fisher Scientific displayed a web price of $1,919.59 each for the Seraseq ctDNA MRD Panel Mix (SeraCare 0710-2146, 4 x 200 ng)

On 2026-09-25 Fisher Scientific displayed a web price of $919.82 each for Seraseq ctDNA Complete Reference Material AF0.1%, 1 x 5 mL

SeraCare lists Seraseq ctDNA Complete Reference Material AF0.1% as 125 ng of DNA in a single 5 mL vial of plasma-like matrix

On 2026-09-25 SeraCare's own web store did not display a price for its ctDNA reference materials without sign-in ('Please sign in to view pricing')

Twist's cfDNA Pan-Cancer Reference Standard v2 set is seven tubes of 300 ng at 0%, 0.1%, 0.25%, 0.5%, 1%, 2% and 5% VAF, and its product sheet prints no price

Horizon's Mimix Multiplex I cfDNA Reference Standard Set is four 350 ng vials in Tris-EDTA at 0%, 5%, 1% and 0.1% allele frequency, with no price displayed on the product page

On 2026-09-25 thermofisher.com displayed USD 490.00 each for AcroMetrix Multi-Analyte ctDNA Plasma Control A (RUO), one vial of 2 mL plasma at 60 ng/mL DNA

On 2026-09-25 fishersci.com displayed $1,617.00 per pack of 1 for the same AcroMetrix Multi-Analyte ctDNA Plasma Control A (RUO)

CMS Medicare Coverage Database article A58376 (revision effective 2026-08-06) names minimal-residual-disease tests from eight companies: Natera, NeoGenomics, Exact Sciences, Personalis, Guardant, SAGA Diagnostics, Veracyte and Naveris

MolDX LCD L38779 requires a minimal-residual-disease test to complete a MolDX technical assessment confirming the policy's analytical validity, clinical validity and clinical utility criteria

A fast-following reference-material vendor could not win MRD-laboratory customers without matching this candidate's characterization dataset and traceability documentation (the class-3 residue of REQ-0028 Read ISO 17034; its documentary twin - what CLIA, CAP and the AMP/CAP guideline require - is drafted separately as published and registry claims)

MRD laboratories would choose, or pay more for, ctDNA reference material from an ISO 17034-accredited producer over the incumbents' ISO 9001/13485-manufactured material (recorded as class 3 so that the incumbents' accreditation status is not read as demand evidence)

The P0 the original shape intended use of idea-003 - which includes use during 'ongoing performance monitoring' of tumor-informed ctDNA minimal residual disease assays that laboratories run on patient specimens - is consistent with the condition in 21 CFR 809.10(c)(2)(i) that an RUO-labeled product be 'in the laboratory research phase of development, and not represented as an effective in vitro diagnostic product'

In FDA's establishment registration and device listing database, Illumina, Inc. lists TruSight Oncology DNA Control, DNA Control v2, RNA Control and RNA Control v2 under product code SCU (21 CFR 866.5910; product listing created 2024-11-07), and SensID GmbH lists the Idylla MSI FFPE Reference Set and Idylla EGFR Reference Set (FFPE) under product code NZB (21 CFR 866.5910; product listing created 2025-12-12)

At a cfDNA input of 10-30 ng (about 3,000-9,100 human haploid genome equivalents at 3.3 pg per haploid genome), the Poisson-expected number of mutant molecules of any single variant is about 0.3-0.9 at 0.01% VAF and about 0.03-0.09 at 0.001% VAF, so that roughly 40%-74% of such inputs at 0.01% VAF and roughly 91%-97% at 0.001% VAF contain no mutant copy of that variant (P(0) = e^-N)

Each of this panel's levels below 0.1% VAF can be value-assigned by gravimetric dilution from a parent level whose variant fraction is digital-PCR-quantified at or above 0.1% VAF into a diluent whose own wild-type cfDNA copy concentration is digital-PCR-quantified, with a stated expanded uncertainty (k=2) no larger than 35% relative that includes dilution, between-unit heterogeneity and a characterized limit-of-blank (background) term, and with the assigned value labelled as derived by dilution rather than directly measured

Across at least three cfDNA extraction methods in routine use by MRD laboratories, the spiked variant-bearing fragments in this panel are recovered at the same efficiency as the endogenous donor-plasma cfDNA, within a pre-specified tolerance, so that the variant allele fraction measured after extraction matches the assigned pre-extraction value within the panel's stated uncertainty

Active MolDX LCD L38779 (the related LCD of billing-and-coding article A58376, which lists code 0340U) provides criteria-gated Medicare coverage for tumor-informed minimal residual disease testing in solid tumors, so that a 0340U service meeting its criteria is covered and payable at the CLFS national limitation amount rather than merely priced on the fee schedule

MolDX LCD L38779 conditions coverage of a minimal residual disease test on a MolDX technical assessment whose analytical-validity criteria require the test's analytical sensitivity (limit of detection) to be demonstrated with material of known variant allele fraction, without naming a required source, supplier, commutability standard or accreditation for that material

At this panel's lowest assigned level, the expected number of tumor-derived variant molecules per supplied vial, summed over all variants the panel certifies and computed from the vial's measured cfDNA genome-equivalent content (at 3.3 pg per haploid genome) times the assigned tumor fraction times the number of certified variants, is at least 100, so that Poisson vial-to-vial heterogeneity is no more than 10% relative; at a vial holding about 15,000 genome equivalents this requires at least about 670 certified clonal variants at 0.001% and about 67 at 0.01%

In the unspiked pooled-donor-plasma lot used as this panel's matrix, measured by an error-corrected sequencing method at every genomic position whose variant the panel certifies, the background variant allele fraction at each such position (donor germline or clonal-hematopoiesis variants plus method error) is no greater than one-tenth of the panel's lowest assigned level, and positions that fail this test are excluded from certification

A bottom-up cost-of-goods build-up for one panel of this candidate, stated at a named annual production volume and restated at one-tenth and at ten times that volume, and itemizing donor-plasma purchase and infectious-disease screening, variant-bearing spike material, per-lot background characterization of the plasma pool, per-lot homogeneity and stability testing, digital-PCR and gravimetric value assignment, cold-chain packaging and shipping, and amortized ISO 17034 surveillance and reassessment cost, yields a fully loaded per-panel cost below the $1,919.59 distributor price displayed for the Seraseq ctDNA MRD Panel Mix on 2026-09-25 (claim 117unconfirmed) at the named volume

Published measurements of total cell-free DNA concentration in plasma from healthy donors report central values (median or mean) at or below 10 ng per mL of plasma, so that a panel unit supplying the 10-30 ng of native cfDNA that one laboratory extraction consumes (claim 133unconfirmed) must contain at least 1-3 mL of native donor plasma per extraction replicate unless the matrix is supplemented with non-native DNA

ISO 17034 requires a reference material producer to assess the homogeneity and the stability of each reference material it produces within its accredited scope, so an initial ISO 17034 accreditation assessment covering this panel cannot be completed before at least one lot of the panel has been produced and assessed for homogeneity and stability; A2LA's stated three-to-six-month time to accreditation (claim 82unconfirmed) therefore runs after first-lot production, not in parallel with it

The variant-bearing source material from which this panel's spike fragments are produced (a tumor cell line, its chromatin, or a synthetic construct) is obtainable from a named source under supply or material-transfer terms that permit its use in manufacturing a reference material that is sold commercially

The current CAP Molecular Pathology checklist (MOL.36118 NGS Lower Limit of Detection as revised from the 2020 edition, or its successor) requires a laboratory establishing the limit of detection of a ctDNA laboratory-developed test to use third-party reference material with stated traceability or measurement uncertainty, rather than permitting in-house contrived samples, spiked plasmids or cell-line mixtures

Every independent claim of US11215622B2 (Covaris, Generation of cfDNA reference material) requires both formaldehyde treatment of chromatin and acoustic shearing of the fixed chromatin, so a spike-fragment production route using neither step does not practise every element of any independent claim of that patent

Every independent claim of US9499870B2 (Natera, Cell free DNA diagnostic testing standards) is limited to a prenatal nucleic acid proficiency-testing standard (composition, method of making, or kit)

No independent claim of US10577655B2 (Natera, Cell free DNA diagnostic testing standards) recites a cancer or tumor nucleic acid proficiency-testing standard, or a composition combining a majority nucleosomal nucleic acid preparation with a minority variant-bearing nucleosomal preparation from a different cell source

The pooled human donor plasma used as this panel's matrix is available from at least one named supplier under donor-consent and supply terms that permit incorporating it into a commercially sold product and genetically characterizing the pool at the panel's certified variant positions

US tumor-informed ctDNA MRD assay developers and molecular laboratories will pay a net price, after any distributor margin, of $1,500-$3,000 per multi-level panel of this candidate (an unspiked blank plus at least three tumor-fraction levels in pooled donor plasma, each with a stated expanded uncertainty) and $400-$900 per vial for its daily-use single-level control

Annual US demand for this candidate's multi-level panel available to one new third-party supplier by year 3 is between 2 and 400 panels, derived as 8-60 buying organisations (claims 125, 12) x 3-20 panels per organisation per year x a 10-30% capture share (claim 47unconfirmed)

If this candidate's daily-use single-level control is sold for run-by-run performance monitoring of patient MRD testing, annual US demand available to one new supplier by year 3 is between 500 and 5,000 vials, derived as 30-60 laboratories (claim 12unconfirmed) x about 250 run-days per year x one control vial per run-day x a 10-30% capture share (claim 47unconfirmed)

A US laboratory buying the Seraseq ctDNA MRD Panel Mix (SeraCare 0710-2146, 4 x 200 ng) direct from SeraCare/LGC pays a net price within 25% of the $1,919.59 Fisher Scientific web price recorded on 2026-09-25 (claim 117unconfirmed), rather than a materially lower direct price of the kind the $490 thermofisher.com versus $1,617 fishersci.com listings of AcroMetrix Multi-Analyte ctDNA Plasma Control A show (claims 123, 124)

At equal nominal tumor-fraction levels, US tumor-informed MRD assay developers will pay at least 25% more for a reference panel in native pooled human donor plasma with a stated expanded uncertainty at every level than for the Tris/EDTA-buffer Seraseq ctDNA MRD Panel Mix, whose datasheet states no uncertainty at any level (claims 101, 111)

At least 10 US organisations currently develop tumor-informed ctDNA minimal residual disease assays without themselves reporting patient MRD results from a CLIA laboratory (IVD kit manufacturers, pharma or CRO assay-development groups, academic or research laboratories)

In FDA's establishment registration and device listing database (openFDA device/registrationlisting.json, query products.product_code:QIG, 2026-09-26), Maine Molecular Quality Controls, Inc. lists BCR-ABL1 control panels for Cepheid's Xpert BCR-ABL assays - including 'Xpert BCR-ABL IS p210 Linearity Panel C207' and 'Xpert BCR-ABL 0%IS' - under product code QIG (Quality Control Material, Genetics, RNA; Class II; 21 CFR 866.5910; submission type 510(k) Exempt), while openFDA's 510(k) database returns no record under product code QIG and no Maine Molecular clearance for a BCR-ABL control; Cepheid's Xpert BCR-ABL Ultra (K190076 (an FDA 510(k) clearance number)) is indicated for quantitation of BCR-ABL1 transcripts in CML patients during monitoring of TKI treatment. That is, a third-party multi-level quality control material for an oncology treatment-monitoring assay is commercially distributed under 866.5910 as 510(k)-exempt without a 510(k)

Use of a quality control material 'during assay validation' of a tumor-informed ctDNA minimal residual disease assay, as idea-003's P2 clinical QC material at launch intended use states, falls within 21 CFR 866.5910(a)'s identification of a device 'intended to help monitor reliability of a test system by detecting analytical deviations', and is not a use different from the intended use of legally marketed devices of that generic type within 21 CFR 866.9(a)

A quality control material built on pooled human donor plasma carrying native cell-free DNA, spiked with variant-bearing fragments, has 'existing or reasonably foreseeable characteristics of commercially distributed devices within that generic type' for 21 CFR 866.5910 within the meaning of the introductory text of 21 CFR 866.9, even though 866.5910(a) names only recombinant, synthetic and cell line-based DNA controls

FDA's special control for 21 CFR 866.5910, 'Class II Special Controls Guidance Document: Quality Control Material for Cystic Fibrosis Nucleic Acid Assays' (issued 2007-01-10), states its recommendations may also apply to other QC materials used in genetic tests, and recommends: evaluation of matrix effects and of extraction; description of the base matrix and donor material; value assignment and traceability for each genetic variation; real-time, opened/closed and shipping-stress stability on multiple lots; reproducibility at 3 or more sites, at least two external, using three lots on different days and operators; performance testing on FDA-cleared or approved assays or an accepted reference method; and labeling that certifies human blood-derived components were tested negative for communicable disease agents per 21 CFR Part 610

idea-003's daily-use single-level control is assigned at a tumor fraction at which, at the cfDNA input per extraction stated on its label, the expected number of tumor-derived variant molecules summed over the certified variants a customer's tumor-informed MRD assay is designed to track is at least 3 (computed at 3.3 pg per haploid genome), so that an in-control run contains at least one mutant molecule with probability of at least 95% (P(0) = e^-N), and the control's labelling states that expected molecule count and its zero-copy probability

idea-003's labelling claims monitoring of inter-run precision only at levels where the expected number of tumor-derived variant molecules per extraction, summed over the certified variants a customer's tumor-informed MRD assay tracks, is at least 100 (Poisson sampling coefficient of variation no more than 10%), and restricts every level below that count to monitoring of qualitative detection

Each lot of idea-003 is supplied with a certified variant list together with a tumor-proxy DNA (the undiluted variant-bearing spike source) and a normal-proxy DNA (the unspiked donor-plasma pool) in quantities sufficient for the tumor and matched-normal sequencing a tumor-informed MRD assay requires to design its patient-specific panel, and at least one external laboratory running a tumor-informed MRD assay has designed a panel against a lot of this material from those components

As of 2026-09-26 no tumor-informed circulating tumor DNA minimal residual disease assay for solid tumors holds FDA 510(k) clearance, De Novo (De Novo classification request) authorization or premarket (PMA (premarket approval)) approval

The BLOODPAC MRD Analytical Validation Working Group consensus recommendation for tumor-informed ctDNA MRD assays (JCO Precision Oncology 2026, PMID 41533993) states that contrived samples must be shown to be functionally comparable with patient samples through a contrived sample functional characterization (CSFC) study to be acceptable for use in analytical validation

Palmetto GBA's MolDX Technical Assessment FAQs (April 2025), the program documentation for the technical assessment that LCD L38779 requires of non-FDA-approved MRD tests, state that purchased reference material or contrived samples may be used in analytical validation (including establishing limit of detection), and name no required source, supplier, commutability standard or accreditation for that material

idea-003's daily-use single-level control is assigned at a mean per-variant variant allele fraction of 0.03% (a tumor fraction of about 0.06% for heterozygous variants in diploid regions) in a single-use vial delivering at least 30 ng (at least 9,100 haploid genome equivalents at 3.3 pg per haploid genome) of cfDNA as measured by digital PCR, is value-assigned by a single gravimetric dilution step from the panel's digital-PCR-measured 0.1% level, and a direct digital-PCR measurement of the 0.03% level on at least 1 µg of pooled cfDNA input across at least three sentinel variants agrees with the gravimetric value within the combined expanded uncertainty (k=2)

In the unspiked pooled-donor-plasma lot used as idea-003's matrix, error-corrected (duplex) sequencing of at least 3 µg of pool cfDNA at every certified variant position observes, summed over all certified positions, a background variant allele fraction no greater than one-tenth of the panel's lowest assigned level, and at each individual certified position a 95% upper bound on background of no more than 1e-5 (0.001%), with positions failing either test excluded from certification

idea-003's variant-bearing spike is produced from a tumor cell line with a matched normal cell line from the same individual, drawn from a banked master stock, in which at least 1,200 clonal variants (at least 150 if the panel's lowest level is 0.01%) are certified with a measured allele copy fraction, and at least 95% of certified variants retain that allele copy fraction within 20% relative across the stock used for three consecutive production lots

For idea-003's pilot lot, an error-corrected sequencing measurement of aggregate variant allele fraction summed across the certified variant set, run on at least 100 ng of cfDNA per replicate and calibrated by ratio to the digital-PCR-measured 0.1% level in the same sequencing run, agrees with the gravimetrically assigned value at the 0.01% level, and at the 0.001% level if that level is retained, within the combined expanded uncertainty (k=2)

Across three consecutive production lots of idea-003, each built on an independently sourced donor-plasma pool, the daily-use control's assigned value lies within 20% relative of its nominal level and the three lots' expanded-uncertainty intervals (k=2) mutually overlap

At least one establishment registered with FDA that lists a device under 21 CFR 866.5910 (product code SCU, NZB or QIG) also offers contract manufacture of nucleic-acid quality control materials to third parties, so that idea-003 could be made under an existing ISO 13485 / 21 CFR 820 quality system rather than one built from a standing start

At least one US supplier of pooled human donor plasma will supply a single custom pooled lot of at least 10 L, with every donation tested for the agents 21 CFR 610.40 requires and donor-level test records supplied, so that one year of idea-003 at Commercial's planning volumes (claims 150 and 151: 50 panels and 2,000 daily-control vials) can be filled from one plasma pool carrying one background characterization

At healthy-donor plasma cfDNA concentrations of 5-20 ng per mL, the at least 3 ug of pool cfDNA that idea-003's per-pool duplex background measurement requires (claim 167unconfirmed) corresponds to at least 150-600 mL of pool plasma per pool before extraction losses, and the 33-100 ug that Technology states a 0.001% floor would require corresponds to at least 1.65-20 L, which is comparable to or larger than the roughly 5-16 L of plasma one year of product at Commercial's planning volumes would fill

No live, enforceable US patent held by an incumbent cfDNA/ctDNA reference-material or liquid-biopsy manufacturer (LGC Clinical Diagnostics/SeraCare, Revvity/Horizon Discovery, Twist Bioscience, Natera, Guardant Health, Illumina/Grail, Roche or Bio-Rad) has an independent claim reading on (a) a contrived plasma reference material retaining native cell-free DNA fragmentomic profile, (b) value-assigning levels below 0.1% VAF of such a material by gravimetric dilution from a digital-PCR-quantified parent into a digital-PCR-quantified diluent, or (c) monitoring the analytical performance of a ctDNA minimal residual disease assay run-by-run with a spiked quality-control material, as idea-003's P1 derived-value bottom levels mechanism and P2 clinical QC material at launch intended use describe

The combination idea-003's P1 derived-value bottom levels mechanism specifies - value-assigning levels below 0.1% VAF in a native-cfDNA pooled donor-plasma matrix by gravimetric dilution from a digital-PCR-quantified parent into a diluent whose wild-type cfDNA copy concentration is digital-PCR-quantified, with an uncertainty budget comprising dilution, between-unit heterogeneity and a characterized limit-of-blank term - is not disclosed in any single prior-art document found by a patentability search

The tumor cell line and matched normal cell line from which idea-003's variant-bearing spike is produced are available under licence or material-transfer terms, and were derived under donor consent, that permit (a) commercial redistribution to customers of DNA extracted from each line as the tumor-proxy and normal-proxy materials described in claim 162unconfirmed, and (b) disclosure to customers of a certified list of that individual's variants at the panel's certified positions

At a net price of $400-$900 per single-use vial, at least one in ten US laboratories running tumor-informed ctDNA MRD assays on patient specimens would use idea-003's daily-use single-level control (native pooled-donor plasma, mean per-variant VAF about 0.03%, at least 30 ng per vial, labelled with its expected molecule count and zero-copy probability and, for low-plex assays, for qualitative detection only) as their run-by-run external control, in place of in-house contrived material - including material made by diluting the buffer-format Seraseq ctDNA MRD Panel Mix's 0.05% level into their own plasma at a per-run cost of roughly $80 (claims 111, 117, 166)

At Commercial's planning volumes (50 multi-level panels and 2,000 daily-control vials per year, claims 150 and 151) and the low end of claim 149unconfirmed's prices ($1,500 per panel, $400 per vial), idea-003's annual revenue of about $875,000 exceeds its fully loaded annual cost of goods plus the recurring annual cost of the 21 CFR 866.5910 obligations claim 159verified describes (QMSR quality system, establishment registration and device listing, UDI (unique device identifier), and complaint and MDR (medical device report) handling)

From a standing start, first commercial distribution of idea-003 as a 21 CFR 866.5910 device - which requires a documented ISO 13485 / 21 CFR 820 quality system with design controls, UDI and complaint handling before distribution (claim 159verified) and, per the P2 clinical QC material at launch plan, three production lots on independently sourced donor-plasma pools (claim 170unconfirmed) - takes longer than the 9-15 months claim 50unconfirmed states for the RUO-era shape

The one-time cost of idea-003's pivot-P2 clinical QC material at launch fixed layer - a 21 CFR 820 / ISO 13485 quality system with design controls, UDI and complaint and MDR handling (claim 159verified), the special-control design-verification study set (claim 158unconfirmed), and three production lots (claim 170unconfirmed) - fits inside the low-single-digit-million first-revenue budget that claim 20unconfirmed states without that layer

At least one FDA-registered establishment that lists a device under 21 CFR 866.5910 (product code SCU, NZB or QIG) would quote to manufacture and release idea-003's daily-use single-level control under its own quality system at a per-vial toll price below $400, the low end of claim 149unconfirmed's per-vial price range

Since 2016, at least one of LGC Clinical Diagnostics/SeraCare, Revvity/Horizon Discovery, Twist Bioscience or Thermo Fisher Scientific has publicly announced in-licensing, or acquiring as a single asset, a nucleic-acid reference-material or quality-control-material production method developed by a third party (the revealed-behaviour twin of claim 51unconfirmed)

A ctDNA MRD quality control supplied as purified DNA in buffer is added after a laboratory's cfDNA extraction step and so does not monitor extraction, whereas idea-003's control, supplied in pooled human donor plasma, is extracted alongside patient specimens and so falls within the complete analytic process that 42 CFR 493.1256 requires control procedures to monitor

As of 2026-09-26 no commercially available US ctDNA reference or quality control material supplies a characterized level below 0.1% variant allele fraction in a human plasma matrix; the one incumbent product found with levels below 0.1% (Seraseq ctDNA MRD Panel Mix, claim 111unconfirmed) is purified DNA in Tris/EDTA buffer

A US laboratory running a tumor-informed ctDNA minimal residual disease assay on patient specimens will design, validate and maintain a dedicated patient-specific assay panel against a quality control material's certified variant list, so that it can run that material as its routine run-by-run control

A US laboratory director validating a tumor-informed ctDNA minimal residual disease assay will accept reference-material levels below 0.1% VAF whose values are labelled as derived by gravimetric dilution rather than directly measured as sufficient support for the limit-of-detection claim the laboratory publishes

A US laboratory that adopts a purchased daily-use ctDNA MRD quality control uses one vial of it on every patient run-day, rather than reserving it for periodic verification runs while running in-house control material day to day

No incumbent reference-material vendor (LGC Clinical Diagnostics/SeraCare, Revvity/Horizon Discovery, Twist Bioscience or Thermo Fisher Scientific) commercially distributes a human-plasma-matrix ctDNA control with characterized levels below 0.1% VAF before idea-003's first commercial distribution

Because no tumor-informed ctDNA minimal residual disease assay holds FDA clearance or approval (claim 163unconfirmed), FDA would accept performance testing of idea-003 on laboratory-developed tumor-informed MRD assays, or against digital PCR as an accepted reference method, as meeting the performance-testing recommendation of the 21 CFR 866.5910 special-controls guidance (claim 158unconfirmed)

At least one published analytical validation or laboratory description of a commercial tumor-informed ctDNA minimal residual disease assay (for example Signatera, RaDaR, NeXT Personal or Haystack MRD) describes a run-level positive control that is run on a fixed panel designed against a reference material or cell line, rather than on patient-specific material with the patient's own panel

Neither 42 CFR 493.1256 nor the current CAP Molecular Pathology checklist requires a laboratory running a tumor-informed ctDNA MRD assay, whose panel differs for every patient, to control each patient-specific panel; a control material run on a separate fixed panel designed against that material's own certified variants can satisfy the laboratory's run-level control requirement

In the most recent CMS Medicare Physician & Other Practitioners utilization file, CPT/PLA codes for tumor-informed ctDNA minimal residual disease tests billed by laboratories other than Natera account for at least one-third of national Medicare fee-for-service tumor-informed MRD test volume, so that the run-by-run control demand claim 151unconfirmed derives across 30-60 laboratories is not concentrated in a single laboratory